Evidence updated August 7, 2026. Concordia Men's Health currently lists medication-only Compounded Tirzepatide at $399 for a monthly plan, $1,139 for three months prepaid, or $2,159 for six months prepaid. The prepaid totals equal $379.67 and $359.83 per month for comparison, but the full selected term is prepaid rather than billed at those effective monthly amounts.
These are CMH cash prices for one specific compounded offering. They are not the national price of tirzepatide, an insurance estimate, or the cash price of Zepbound or Mounjaro. Compounded drugs are not FDA-approved and are not FDA-approved generic drugs. A licensed provider must review the private assessment and decide whether treatment and any prescription are appropriate.
Current CMH compounded tirzepatide cash prices
| Medication-only term | Current cash price | Effective monthly arithmetic | Payment and fulfillment reading |
|---|---|---|---|
| Monthly | $399 | $399.00 | One monthly plan price, subject to current commercial terms. |
| Three months prepaid | $1,139 | $379.67 | The full three-month amount is prepaid after the required provider decision; pharmacy fulfillment remains monthly while treatment continues. |
| Six months prepaid | $2,159 | $359.83 | The full six-month amount is prepaid after the required provider decision; pharmacy fulfillment remains monthly while treatment continues. |
The comparison arithmetic is $1,139 divided by three and $2,159 divided by six, rounded to the nearest cent. It does not create $379.67 or $359.83 monthly installment plans. The selected checkout disclosure, order confirmation, Terms & Conditions, and Refund Policy control the actual transaction.
Prices and terms can change. Confirm the current offer before purchase instead of treating an older search result, screenshot, social post, or cached page as a quote.
These figures describe CMH's approved cash-price structure. They do not establish that checkout or payment is active or that a purchase can currently be completed; payment activation remains a separate operational gate.
What “without insurance” means here
This article answers a direct-pay cash question. It does not predict whether an insurer will cover or reimburse a product, whether a deductible applies, whether prior authorization is required, or whether a manufacturer program is available. Those answers can differ by person, plan, exact product, and time.
CMH does not promise insurance coverage or reimbursement for its compounded tirzepatide offering. If you compare this cash price with an insured price or a manufacturer-supported price elsewhere, keep the exact product, eligibility rules, total out-of-pocket amount, term, and included commercial scope visible. A price attached to one category should not be transferred to another.
Tirzepatide is an ingredient, not a complete price identity
A search for “tirzepatide cost” can surface FDA-approved branded products, compounded preparations, medication-only plans, care-program bundles, and prices that depend on insurance or manufacturer-program eligibility. Those are not interchangeable price categories.
The FDA states that compounded drugs are not FDA-approved and are not FDA-approved generic drugs. FDA does not verify compounded drugs for safety, effectiveness, or quality before they are marketed. The agency also describes concerns with unapproved GLP-1 drugs used for weight loss, including products containing tirzepatide.
CMH's current offering is compounded tirzepatide. It must not be presented as Zepbound, Mounjaro, an FDA-approved generic, or the same as an approved product. The price table above belongs only to CMH's current medication-only Compounded Tirzepatide path. For the product and provider-decision boundary, read the tirzepatide product-truth guide.
Use a cash-cost ladder instead of one monthly-looking number
A useful cash comparison keeps five levels in order. This cash-cost ladder is an editorial commercial tool, not a clinical score, treatment selector, insurance estimate, or quality rating.
- Name the exact category. Record the brand or compounded preparation rather than writing only “tirzepatide.”
- Record the amount actually committed. Keep $399 monthly separate from $1,139 or $2,159 prepaid.
- Calculate, but label, the monthly equivalent. Use effective monthly arithmetic only for comparison and never relabel it as an installment offer.
- Separate payment from fulfillment. A prepaid term can still involve monthly pharmacy fulfillment while provider-directed treatment continues.
- Attach the change and exit rules. Note current renewal, cancellation, shipped-medication, unshipped-allocation, and provider-decision boundaries before comparing totals.
This order prevents a low monthly-looking figure from hiding a larger prepaid commitment or a different product category. The FTC Health Products Compliance Guidance explains that objective health claims need appropriate support and that qualifications must be evaluated as part of the full message. For a price page, the same complete-impression discipline means the headline, product identity, payment term, inclusions, qualifications, policies, and checkout should not contradict one another.
Medication-only pricing is not Momentum Program pricing
CMH's current source-controlled offer keeps medication-only care separate from the 90-Day Momentum Program. The $399, $1,139, and $2,159 figures in this article are medication-only Compounded Tirzepatide prices. They must not be used as Momentum prices or to imply that a medication-only customer receives the full Sprint structure, founder services, class experience, or other Momentum deliverables.
Current CMH materials describe the medication-only route as provider-reviewed care with medication when prescribed, monthly pharmacy fulfillment during prepaid terms, and the commercial services included under the current arrangement. The exact current checkout and policy language controls what is included. Review the FAQ with the Terms and Refund Policy rather than relying on a price card alone.
The current source-controlled medication-only offer lists term-based prices rather than a dose-step price table. That commercial structure does not determine a dose or guarantee that any dose, medication, or continuation will be appropriate. Those decisions remain with the licensed provider.
Prepayment does not guarantee treatment through the full term
Current CMH terms state that a card may be authorized and that actual capture follows provider review, approval, and prescription where required. A prepaid purchase does not guarantee provider approval, a prescription, medication, a particular dose, uninterrupted supply, or continuation for the entire term.
Pharmacy fulfillment occurs monthly while treatment continues. A provider may make a different decision at review or follow-up. The provider-review guide explains why the licensed provider—not a price table, an algorithm, or CMH's editorial team—owns the individual medical decision.
Do not send symptoms, diagnoses, current medicines, side effects, laboratory values, or other private health information through public comments, social messages, ordinary email, or generic forms. Medical information belongs only in the approved secure clinical route.
Refund and renewal rules change the practical cost
A cash comparison is incomplete without the rules for the selected term. CMH's current public Refund Policy distinguishes medication accepted by the carrier from medication allocations that have not shipped. It also keeps medication-only rules separate from Momentum Program rules. Exact checkout allocations and the order confirmation control the calculation.
Current terms describe automatic renewal for selected plans unless renewal is canceled before processing. Preventing a future renewal is different from requesting a refund for the current term. Read the current renewal disclosure, cancellation route, and refund terms before authorizing a purchase.
If a price comparison omits these conditions, add them to the cash-cost ladder. The useful question is not only “What is the effective amount per month?” It is also “What total am I committing, what is fulfilled monthly, what can renew, and what rules apply if the provider-directed path changes?”
Questions to answer before relying on a tirzepatide price
- What exact branded product or compounded preparation does the price identify?
- Is the displayed amount monthly, prepaid, or only an effective monthly calculation?
- What total amount is authorized and charged, and at what point in the provider-review process?
- What does the selected commercial term include and exclude?
- Does the price belong to medication-only care or a broader program bundle?
- How often does pharmacy fulfillment occur during a prepaid term?
- What renews automatically, and how must renewal be canceled?
- How do the current terms treat shipped medication and unshipped allocations?
- Which licensed provider owns approval, prescription, dose, and continuation decisions?
- Which coverage, reimbursement, availability, prescription, continuation, or outcome is not guaranteed?
For current CMH medication-only Compounded Tirzepatide, the cash prices are $399 monthly, $1,139 for three months prepaid, and $2,159 for six months prepaid as of August 7, 2026. The effective monthly arithmetic is $379.67 and $359.83, but those are comparison figures—not monthly installment offers.
Review the current CMH overview and current public policies for the commercial route. For ingredient-level differences without turning a general comparison into personal advice, use the semaglutide-versus-tirzepatide guide. The direct assessment link is omitted because its automated first-step check remains blocked; this article does not reinterpret or clear that separate route defect.
This article is general education and commercial-term explanation, not medical, insurance, tax, financial, or legal advice. It does not determine eligibility, recommend or select treatment, provide dosing or interaction guidance, predict coverage, or replace current checkout terms, complete product information, and a licensed provider's judgment.